Viral hepatitis: "E" is for equitable elimination

Same author

Global Trends in National Alcohol Control Policies Between 2010-2019.

JHEP reports : innovation in hepatology·2026

Same author

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

The Lancet regional health. Europe·2026

Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026

Same author

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

The Lancet regional health. Europe·2026

Same author

A people-first, systems-oriented approach to liver disease in HIV infection.

Nature reviews. Gastroenterology & hepatology·2026

Same author

Socioeconomic Inequalities in Receipt of Curative-Intent Treatment and Survival After Surveillance-Detected Hepatocellular Carcinoma: A Nationwide Cohort Study.

Alimentary pharmacology & therapeutics·2026

Same journal

Retraction notice to "Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population" [J Hepatol 58 (2013) 271-277].

Journal of hepatology·2026

Same journal

Optimising the screening strategy for early-stage hepatocellular carcinoma.

Journal of hepatology·2026

Same journal

Corrigendum to: "A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse" [J Hepatol (2014) 60: 782-91].

Journal of hepatology·2026

Same journal

Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort.

Journal of hepatology·2026

Same journal

Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.

Journal of hepatology·2026

Same journal

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal of hepatology·2026

Related Experiment Videos

Viral hepatitis: "E" is for equitable elimination

Related Concept Videos

Global Trends in National Alcohol Control Policies Between 2010-2019.

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

A people-first, systems-oriented approach to liver disease in HIV infection.

Socioeconomic Inequalities in Receipt of Curative-Intent Treatment and Survival After Surveillance-Detected Hepatocellular Carcinoma: A Nationwide Cohort Study.

Retraction notice to "Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population" [J Hepatol 58 (2013) 271-277].

Optimising the screening strategy for early-stage hepatocellular carcinoma.

Corrigendum to: "A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse" [J Hepatol (2014) 60: 782-91].

Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort.

Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Related Experiment Videos

Viral hepatitis: "E" is for equitable elimination

Related Concept Videos

Related Articles

Global Trends in National Alcohol Control Policies Between 2010-2019.

Assessing Europe's policy readiness to confront the MASLD/MASH public health threat.

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

A people-first, systems-oriented approach to liver disease in HIV infection.

Socioeconomic Inequalities in Receipt of Curative-Intent Treatment and Survival After Surveillance-Detected Hepatocellular Carcinoma: A Nationwide Cohort Study.

Retraction notice to "Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population" [J Hepatol 58 (2013) 271-277].

Optimising the screening strategy for early-stage hepatocellular carcinoma.

Corrigendum to: "A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse" [J Hepatol (2014) 60: 782-91].

Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort.

Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial.

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.